<table sstyle="width:80%" align="center" border=1>
<tr>
<th>mv</th>
<th>dw</th>
<th>HMMCrowd</th>
</tr>
<tr>
<td width=33%>
[70, 73] ameliorate crisis,<br>[74, 78] recurrent bone pain.<br>[170, 172] painful episodes<br>[180, 182] febrile illness<br>[190, 192] admission rate<br>[204, 206] mean hematocrit<br>[227, 238] transfusion rate, presence of hepatomegaly, splenomegaly, and jaundice<br>[249, 253] side-effect.<br></td>
<td width=33%>
[70, 73] ameliorate crisis,<br>[74, 78] recurrent bone pain.<br>[170, 172] painful episodes<br>[180, 182] febrile illness<br>[190, 192] admission rate<br>[204, 206] mean hematocrit<br>[227, 238] transfusion rate, presence of hepatomegaly, splenomegaly, and jaundice<br>[249, 253] side-effect.<br></td>
<td width=33%>
[6, 12] severity of sickle cell anemia.<br>[17, 25] pain in sickle cell anemia (SCA)<br>[29, 35] dehydration, acidosis, and fever<br>[70, 78] ameliorate crisis, especially recurrent bone pain.<br>[129, 135] lower rates of significant painful episodes<br>[169, 172] significant painful episodes<br>[180, 182] febrile illness<br>[190, 192] admission rate<br>[204, 208] mean hematocrit of the<br>[227, 238] transfusion rate, presence of hepatomegaly, splenomegaly, and jaundice<br>[248, 253] significant side-effect.<br>[264, 268] therapeutic and nutritional relevance<br></td>
</tr>
